Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.
Johnson & Johnson pessimists are already worried that Olysio will have a short, happy, busy life and an all-too-sudden end.
Johnson & Johnson pessimists are already worried that Olysio will end up like a mayfly, with a short, happy, busy life and an all-too-sudden end. If the U.K.'s cost-effectiveness gatekeepers offer any indication, they may be correct.
Even drugmakers with steamrolling pharma units need to cut costs sometimes, and Johnson & Johnson fits that bill. To do so, the company will shrink the pension benefits offered to those who are hired--or rehired--after January 1.
Johnson & Johnson's Ethicon unit lost a battle in its ongoing vaginal mesh litigation as a federal jury in West Virginia ordered the company to pay $3.27 million to a woman who claimed the device caused undue pain and serious side effects.
Johnson & Johnson squared off with aggrieved metal-on-metal hip customer Kathleen Herlihy-Paoli in a case that the plaintiffs says could lead to a $5 billion-plus payout. Herlihy-Paoli's claims that the hips leaked metal into her bloodstream, leading to an infection that required the artificial hip to be removed.
Another Big Pharma player is joining the hustle toward an Ebola vaccine as the death toll surpasses 1,900 victims, eclipsing the total number of people who died from the disease in all previous outbreaks combined.
The deadly outbreak of Ebola in West Africa is pushing related vaccine and drug development efforts from first gear into overdrive. Today it's J&J's turn to step up, teaming with the Danish biotech Bavarian Nordic to pair up vaccine components into a new jab with the help of the National Institute of Allergy and Infectious Diseases. And the pharma giant says it can start testing the new combination vaccine in a rushed clinical trial slated to start in early 2015.
Johnson & Johnson and Bayer's Xarelto already heads up the pack of new-age anticoagulants, but the pair isn't quitting while it's ahead. Instead, the drugmakers are looking to expand that market lead with new clinical trials aimed at widening the drug's label.
Long beleaguered by claims related to defective all-metal hip implants, Johnson & Johnson is shoring up for its latest courtroom battle as the company faces the first trial for one of its artificial hip devices.